Skip to main content

letter

. 1988 Feb;25(2):279–280. doi: 10.1111/j.1365-2125.1988.tb03304.x

Biliary excretion of antipyrine and its metabolites after cholecystectomy.

H Mönig, J Wilhelmy, S John, E E Ohnhaus

PMCID: PMC1386487 PMID: 3358892

279

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Danhof M., Breimer D. D. Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers. Br J Clin Pharmacol. 1979 Dec;8(6):529–537. doi: 10.1111/j.1365-2125.1979.tb01040.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Danhof M., Verbeek R. M., van Boxtel C. J., Boeijinga J. K., Breimer D. D. Differential effects of enzyme induction on antipyrine metabolite formation. Br J Clin Pharmacol. 1982 Mar;13(3):379–386. doi: 10.1111/j.1365-2125.1982.tb01389.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Eichelbaum M., Bertilsson L., Säwe J. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. Br J Clin Pharmacol. 1983 Mar;15(3):317–321. doi: 10.1111/j.1365-2125.1983.tb01505.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Eichelbaum M., Sonntag B., Dengler H. J. HPLC determination of antipyrine metabolites. Pharmacology. 1981;23(4):192–202. doi: 10.1159/000137550. [DOI] [PubMed] [Google Scholar]
Vesell E. S. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther. 1979 Sep;26(3):275–286. doi: 10.1002/cpt1979263275. [DOI] [PubMed] [Google Scholar]
Wissel P. S., Kappas A. The absence of significant biliary excretion of antipyrine or its metabolites in humans. Clin Pharmacol Ther. 1987 Jan;41(1):85–87. doi: 10.1038/clpt.1987.14. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES